The Extreme Effects of ‘Not-so-minor’ Concussions:
Chronic Traumatic Encephalopathy Literature Review by Pierson, Alyssa
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Honors Theses, University of Nebraska-Lincoln Honors Program
Spring 3-11-2019
The Extreme Effects of ‘Not-so-minor’
Concussions: Chronic Traumatic Encephalopathy
Literature Review
Alyssa Pierson
University of Nebraska - Lincoln
Follow this and additional works at: http://digitalcommons.unl.edu/honorstheses
Part of the Medical Neurobiology Commons
This Thesis is brought to you for free and open access by the Honors Program at DigitalCommons@University of Nebraska - Lincoln. It has been
accepted for inclusion in Honors Theses, University of Nebraska-Lincoln by an authorized administrator of DigitalCommons@University of Nebraska
- Lincoln.
Pierson, Alyssa, "The Extreme Effects of ‘Not-so-minor’ Concussions: Chronic Traumatic Encephalopathy Literature Review" (2019).
Honors Theses, University of Nebraska-Lincoln. 76.
http://digitalcommons.unl.edu/honorstheses/76
CHRONIC TRAUMATIC ENCEPHALOPATHY 1 
 
 
 
 
The Extreme Effects of ‘Not-so-minor’ Concussions: 
Chronic Traumatic Encephalopathy Literature Review 
Alyssa Pierson 
University of Nebraska- Lincoln 
  
CHRONIC TRAUMATIC ENCEPHALOPATHY 2 
Abstract 
Many of the concerns that people have with chronic traumatic encephalopathy (CTE) have 
already been researched for almost a century, but recently, there has been a big push in CTE 
research. Previous research was done on boxing and football and has now expanded to other 
contact sports and the military.  Risk factors for CTE include repetitive head trauma, the Apoe4 
allele, and age of first exposure to brain trauma. A wide range of symptoms may present with 
CTE, from motor impairment to suicidal ideation. It is believed that a biopsychosocial model 
should be used when approaching the symptoms of CTE patients. Current research is trying to 
determine the main pathology or pathologies of CTE and have determined that there are both 
macroscopic and microscopic pathologies. The only definitive cases of CTE have been 
determined by an autopsy, but with the use of biomarkers and advances in neuroimaging, 
hopefully CTE can be diagnosed in living persons and work can be done to find a treatment. 
  
CHRONIC TRAUMATIC ENCEPHALOPATHY 3 
Background 
 The overall concept of chronic traumatic encephalopathy (CTE) and brain trauma dates 
back almost a century ago. Osnato and Gilberti (1927) are credited with the original concept that 
chronic neurodegeneration might occur after minor brain trauma. They studied 100 clinical cases 
of concussions of the brain, which was defined back then as a blow to the head with loss of 
consciousness with or without posttraumatic amnesia or skull fracture. Through this study, they 
found that several instances in which the clinical symptoms persisted, and secondary 
degenerative changes developed, they termed this ‘traumatic encephalitis’. The following year, 
in 1928, Martland studied the effects of repetitive brain trauma in boxers, he called it “punch-
drunk syndrome”. Boxers did not like the term “punch-drunk syndrome” so it was later named 
dementia pugilistica, which described a physical-psychic syndrome that accumulated over a 
lengthy boxing career. (Tharmaratnam et al., 2018). In 1973, Corsellis, Bruton and Freeman-
Browne described the clinical and neurological features of 15 retired boxers. The study 
conducted in 1973 introduced a relatively stereotyped pattern of structural brain abnormalities. 
These abnormalities included: cerebral atrophy, enlargement of the lateral and third ventricles, 
thinning of the corpus callosum, cavum septum pellucidum with fenestrations and cerebellar 
scarring (Corsellis, Bruton, & Freeman, 1973). Currently, many people follow the guidelines set 
by Omalu and colleagues who were the first to demonstrate the CTE phenomenon in 2005 
through a series of case reports based on autopsy findings of deceased players’ brains. CTE is 
currently defined as brain trauma that is either repetitive, episodic, or a single precipitating event, 
leading to progressive brain neurodegeneration (Tharmaratnam et al., 2018).  
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Epidemiology and Incidence 
Studies aiming to identify the prevalence of CTE in football players have shown 
remarkable, indisputable findings. In the largest ever case series of CTE, involving 202 deceased 
former football players, 87% of them had signs of CTE, including 99% ex-NFL players. The 
magnitude of the disease burden was correlated to level of play, with high school athletes having 
mild CTE, and NFL players showcasing the most severe form of CTE. In this same study, it was 
found that Ex-NFL players were also, if over the age of 50, five times more likely to be 
diagnosed with dementia than the national population averages (Tharmaratnam et al., 2018). The 
exact incidence of CTE is still unknown but it is believed to be attributed to duration of play, 
position, sport, age of first exposure, and genetics. 
Risk Factors 
The primary risk factor for CTE is believed to be repetitive head trauma, which is very 
common in football players, especially NFL football players. In a study done on NFL football 
players, 61% of them have experienced at least 1 concussion within their careers; but, remember 
that brain trauma without a concussion can also lead to CTE. In general, most people recover 
from a single head impact with no CTE, however, experiencing 3 or more concussions is 
correlated to an increased risk of prolonged symptoms. In a sample of 1721 cases of contact 
sport athletes, CTE was reported to be found in 32% of the cases, whereas no cases of CTE was 
found in patients with no prior brain trauma in the control group. This suggests that participating 
in contact sports is a predisposing risk factor in the development of CTE (Tharmaratnam et al., 
2018).  
Research has shown that there may be a genetic susceptibility risk factor for CTE. There 
is an apolipoprotein (Apoe), a 34-kDa glycosylated protein, that is implicated as the primary 
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source of cholesterol transport in the brain for neuronal repair. Individuals possessing Apoe4 
allele have been shown to have an increased risk of poor functional outcome. Compared to other 
isoforms, the Apoe4 variant has been associated with longer recovery times from neurotrauma, 
increased injury severity, and greater cognitive deficits in football players (Tharmaratnam et al., 
2018).  
Another risk factor is age of first exposure (AFE) which is associated with neurological 
and psychiatric dysfunction later in life. Ages 9-12 have been identified as key periods 
corresponding to peak gray and white matter volumes and neurological maturation of the 
hippocampus and amygdala. AFE <12 was associated with more than double the risk of 
cognitive impairment later in life, which included impairments in correlates of apathy and 
depression, but not cognition (Tharmaratnam et al., 2018).  
Mechanisms of Injury 
 The literature to date is not sufficient to determine whether the development of CTE is 
associated with head injury frequency or head injury type (Aldag et al., 2017). It has been 
demonstrated that brain trauma without concussion can also lead to CTE. Over time, tau 
oligomers develop into paired helical, and straight filamentous neurofibrillary tangles (NFTs), 
which interfere with white matter tracts in the brain and cause signaling and communication 
abnormalities through denervation injury (Tharmaratnam et al., 2018). The increased blood-
barrier permeability is due to the inflammatory state which activates cytokine and chemokines, 
allowing unwanted chemicals and hormones in. 
Symptoms 
 Clinical symptoms associated with CTE include chronic psychiatric illness, headache, 
cognitive dysfunction, motor impairment, irritability, aggression, episodic memory impairment, 
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suicidal ideation, rampant mood fluctuations and depression (Aldag et al., 2017). Usually, 
behavioral and mood changes appear before the onset of neurocognitive decline; with the most 
commonly described behavioral features including explosivity, impulsivity, and hopelessness 
followed by suicidality and anxiety (Asken et al., 2016). In 2014, Montenigro and colleagues 
coined the term “traumatic encephalopathy syndrome” (TES) along with various TES subtypes. 
They included five general criteria derived from calculated prevalence of cognitive and 
emotional deficits across reported cases of CTE, three core clinical features, and nine supportive 
features (Asken et al., 2016). The most recent rendition of TES has different requirement and 
was established by Reams and colleagues. This new criterion requires persistence of symptoms 
for at least two years, a history of head trauma exposure, delayed onset following head trauma, 
progressive course, and formal neuropsychological testing corroborating self- or observer-report 
of cognitive dysfunction in the executive, visuospatial, memory, and/or language domain(s) 
(Asken et al., 2016). Symptoms do not present immediately and typically occur in midlife, 
usually decades after the original injury. On average, symptom onset usually occurs around 8 
years after retirement, but it is unclear why this latency period exists. Some researchers believe 
that it is a result of tau propagation from focal to widespread areas, as a consequence of 
progressive axonal disruption.  
Pathologies 
The neuropathology of CTE is usually looked at in two different categories: macroscopic 
and microscopic. The macroscopic changes that are seen are commonly found in the advanced 
forms of CTE and rarely manifest in the early stages. Macroscopically, there may be cerebral 
atrophy, reduced brain mass, enlarged lateral and third ventricles, cavum septum pellucidum, 
pale locus coeruleus, and diencephalon atrophy (Tharmaratnam et al., 2018). The microscopic 
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pathologies are more debated and are multifactorial, they include tau protein aggregation, 
transactive response DNA-binding protein (TDP-43), beta-amyloid plaque (Ab), and 
neuroinflammation. Tau progression is classically found in the perivascular spaces around the 
blood vessels, deep in the cortical sulci (Tharmaratnam et al., 2018). The perivascular 
accumulation of hyperphosphorylated tau (p-tau) at the depths of cortical sulci is thought to be 
unique to CTE and has been proposed as a diagnostic requirement of CTE. The normal function 
of tau protein is to stabilize microtubules; however, aberrant p-tau causes the formation of 
protein aggregates and NFTs, which may contribute to the development of CTE (Lucke-Wold et 
al., 2014). TDP-43 functions as a transcriptional regulator in the central nervous system and this 
pathological feature is not unique to CTE, it is also observed in other neurodegenerative diseases 
(Armstrong 2009; Bosque, Boyer, & Mishra 2013). TDP-43 is a ubiquitously expressed nuclear 
protein and has a high binding affinity for either TG repeats in DNA or UG repeats in RNA. It is 
commonly found co-localized with p-tau NFTs (Tharmaratnam et al., 2018). TDP-43 bound to 
(UG)n elements at the 3’-UTR of tau mRNA and promoted its instability, resulting in a negative 
regulation of tau expression (Gu et al., 2017). Phosphorylated TDP-43, previously identified as 
the common pathologic proteinopathy linking frontotemporal dementia (FTD) and amyotrophic 
lateral sclerosis (ALS) is found in more than 80% of CTE cases (McKee et al., 2016). As tau and 
TDP-43 deposition increases, it has been shown that there is a parallel increase in axonal 
pathology and loss (Stein, Alvarez, & McKee 2014). Beta-amyloid plaque may be found in a 
diffuse pattern in sporadic loci or none at all, so it is not a tell-tale sign of CTE. 
Neuroinflammation is associated with microglial and astroglial activation, potentially playing a 
role in long-term neurodegeneration (Faden, Wu, Stoica, & Loane 2015). 
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There are four phenotypes that were proposed by Omalu and co-workers (Omalu et al., 
2011) that were thought of as parallel pathologies. Phenotype I has sparse to frequent NFTs and 
neuritic threads (NTs) in the cerebral cortex and brainstem. Phenotype II also includes NFTs and 
NTs in the basal ganglia and cerebellum in addition to diffuse amyloid plaques. Phenotype III 
has a combination of moderate to frequent NFTs and NTs predominately in the brainstem with 
absent to sparse NFTs and NTs in the cerebral cortex and basal ganglia with none in the 
cerebellum. Phenotype IV is a combination of absent to sparse NFTs and NTs in the cerebral 
cortex, brainstem, and basal ganglia, an absence of NFTs and NTs in the cerebellum, and an 
absence of diffuse amyloid plaques in the cerebral cortex. 
Although the process begins focally, it gradually spreads to involve widespread regions 
of the brain including the frontal and temporal lobes, medial temporal lobe, diencephalon, and 
brainstem. McKee and colleagues (2013) determined that CTE could be classified into four 
pathological stages based on a stereotyped pattern of structural change and tau pathology. Stage I 
brains are grossly unremarkable, although mild enlargement of the frontal horns of the lateral 
ventricles may be found occasionally. Microscopically, there are isolated perivascular foci of p-
tau NFTs, neurophil threads and astrocytic tangles. This is most commonly seen at the depths of 
cerebral sulci of the superior, dorsolateral, lateral, and inferior frontal cortices. P-tau-positive 
astrocytes are usually found in the subpial region directly overlying the perivascular foci. In 
stage II, macroscopic abnormalities are found in approximately one-half of the cases, including 
mild enlargement of the frontal horns of the lateral ventricles and third ventricle, a cavum 
septum, and pallor of the locus coeruleus and substantia nigra. Microscopically, multiple foci of 
tau pathology are found at the depths of the sulci commonly in the superior, dorsolateral, lateral 
and inferior frontal, the anterior inferior and lateral temporal, inferior and superior parietal, 
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insular and septal cortices. Deep structures such as the substantia nigra, dorsal and median raphe 
and thalamus show mild neurofibrillary degeneration. Beta-amyloid pathology is not found in 
stage II CTE. Most stage III cases of CTE show a reduction in brain weight, mild atrophy of the 
frontal and temporal lobes and enlargement of the lateral and third ventricles. Microscopically, 
NFTs are present diffusely in the frontal, temporal and parietal cortices and are most 
concentrated around small vessels and at the depths of sulci. The majority of cases show TDP-
43-positive neurites and inclusions in the cerebral cortex, medial temporal lobe, diencephalon 
and brainstem. Although most stage III cases of CTE show no beta-amyloid deposition, sparse 
diffuse and neuritic beta-amyloid plaques are found in approximately 13%. Brain weight in stage 
IV is significantly decreased, there may be marked global atrophy of the brain. There is usually 
pronounced atrophy of the frontal and temporal lobes, medial temporal lobe and anterior 
thalamus. The hypothalamic floor is thinned, mammillary bodies are darkly discolored and 
atrophied, and there is marked enlargement of the lateral and third ventricles. Approximately 
two-thirds of subjects will have septal abnormalities including cavum septum, fenestrations, or 
absence. Microscopically, there is widespread neuronal loss, as well as severe tau deposition, as 
clusters of glial tangles and small NFTs in a patchy irregular distribution throughout frontal, 
temporal and parietal cortices. NFTs are found widely distributed throughout the hippocampal 
formation including the dentate gyrus, CA3, CA2, and CA4 regions. The CA1 region is typically 
severely sclerotic, with few remaining neurons. The fourth stage generally involves the 
cerebellum where there is marked loss and distortion of axons throughout the cerebral and 
cerebellar white matter. TDP-43 deposition is severe and widespread with dense accumulations 
of dot-like and thread-like inclusions in neurites and intro-neuronal cytoplasmic inclusions in all 
cases (McKee et al., 2013). 
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Biopsychosocial Model Approach 
Many researchers believe that to obtain a more comprehensive diagnosis, a 
biopsychosocial model should be applied. Existing research has examined convenient samples of 
athletes who donated their brains and were experiencing clinical symptoms prior to their death- 
this has unfortunately led to misleading headlines about the risk of developing CTE pathology 
and estimates of its prevalence which are almost certainly inflated (O’Keefe 2015). Attribution 
of pathological burden and symptom expression needs to be considered in a broad 
biopsychosocial explanatory framework that incorporates these factors in the casual model 
instead of focusing only on a history of repetitive brain trauma as the sole causative factor in the 
development or degree of CTE symptoms (Asken et al., 2016).  
 The environment a particular person develops in may have a large impact on their 
behavior or psyche. Disadvantaged SES predisposes to increased aggression and higher 
susceptibility to depression, two symptoms also seen in CTE (McLoyd 1997). Interaction of SES 
and prenatal development, as well as delayed development, could affect cognitive and neural 
functioning into adulthood as well.  
Some research takes normal aging into account, and compares CTE to the normal aging 
brain, but a lot of the effects seen in CTE are also found in normal aging. Structural brain 
changes associated with normal aging are well-known and include neurofibrillary tangle (NFT) 
development, decreased grey and white matter volume, increased ventricular volume, increased 
white matter hyperintensities on MRI, and default mode network (regions of highly correlated 
functional activity) dysfunction on MRI as well (Andrews-Hanna et al. 2007). Decreased white 
matter integrity is also associated with slowed processing speed and impaired executive function 
(Asken et al., 2016). NFT deposition accompanies the normal aging process and the recently 
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proposed “primary age-related tauopathy” (PART) describes the continuum of severities with 
and without associated cognitive changes (Crary et al. 2014) However, the unique distribution of 
tau deposition in the perivascular spaces of cortical sulci described in CTE differentiates CTE 
from PART, which is associated with NFT formation in the medial temporal lobe and several 
subcortical nuclei. So, contrary to other research, the pathological features of CTE do not 
represent normal or accelerated aging. 
Sleep disturbances may also impact the behavior of a particular person. Sleep is very 
important, recent evidence indicates that sleep enhances the clearance of metabolic waste 
products from interstitial space in the brain via the “glymphatic system (Xie et al. 2013). The 
glymphatic system is thought to rely on the sleep state to relax interstitial spaces enabling 
cerebrospinal fluid (CSF) and interstitial fluid (ISF) to move through and clear metabolic waste 
(Jessen, Munk, Lundgaard, & Nedergaard, 2015). Interstitial space actually expands by up to 
60% during sleep which accelerates the flow of fluids through the glymphatic system. Disruption 
to this system may be particularly relevant to collision sport athletes, who are likely to 
consistently accumulate metabolic waste from concussive and subclinical brain insults, including 
beta-amyloid from recurrent trauma (Giza and Hovda 2014). In many cases, sleep is disturbed 
after a concussion and disordered sleep can be a significant factor in the development of a wide 
range of cognitive, mood, and behavioral problems. 
A Case Study 
A case study was reported by Mez et al. in 2016 of a 25-year-old Division I college 
football defensive linebacker and special teams player. He began playing football at the age of 
six and stopped playing at the beginning of his junior season of college because of the ongoing 
symptoms he experienced. In his football career, he experienced more than 10 concussions, the 
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first of which occurring at age eight. Although CTE was considered, the lack of delay in 
symptom onset, his young age and his family history of depression were the reasons against CTE 
as a primary diagnosis for his death. Focal lesions of CTE have been found in athletes as young 
as 17 years; however, widespread CTE pathology is unusual in such a young football player. 
Prospective studies that include neuropsychological testing with imaging and fluid biomarkers 
will be essential to future improvement in diagnosing CTE in living patients.  
Prevention 
 Currently there are no treatments for CTE, primarily because CTE hasn’t been diagnosed 
in a living person yet. Without treatment strategies available, it is important to prevent severe 
head injuries to mitigate CTE. Protective head gear is important in protecting against penetrating 
injuries, skull fracture, and intracranial hemorrhage, but they do not appear to mitigate the 
incidence or severity of sports-related concussions (Harmon et al., 2013). It is important to 
understand that repeated blows to the head without a concussion can still lead to CTE, kids need 
to be protected from this rick factor. Putting kids into non-contact sports will help mitigate the 
incidence of blows to the head, concussions and CTE.  
Future Research 
Neuroimaging using positron emission tomography (PET), diffusion tensor imaging 
(DTI), functional magnetic resonance imaging (fMRI) may lead to the diagnosis of CTE in living 
patients. One approach is the depletion of molecules associated with CTE pathology (e.g., tau, 
Ab). The second approach is detecting structural or molecular changes as associated with head 
injury, which is thought to contribute to the development of CTE (Aldag et al., 2017). PET can 
detect the presence and distribution of specific molecules using trace amounts of radioactive 
ligands that bind to molecules of interest. Investigators are developing PET radioligands to 
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image pathology associated with CTE, such as aggregations of tau and Ab (Villemangne & 
Okamura 2014; Barrio et al., 1999). Several PET radioligands targeting tau have shown potential 
as CTE biomarkers, some are even in clinical trials. Some challenges with PET are that p-tau 
aggregates are expressed intracellularly, which requires the corresponding imaging ligand to 
cross the blood brain-barrier and cell membrane (Villemagne, Fodero-Tacoletti, Masters, & 
Rowe 2015). DTI revealed significant white matter changes in a high school contact sport athlete 
after a single concussion and have supported a link between axonal abnormalities and executive 
impairment after traumatic brain injuries (Bazarian et al., 2012; Lipton et al., 2009). Researchers 
have used functional magnetic resonance imaging (fMRI) to evaluate functional disruptions in 
both concussive and subconcussive injury groups, even in the absence of overt clinical symptoms 
(Talavage et al., 2010). 
Biospecimen-based biomarkers would be able to provide a more accessible, cost-
effective, and deployable method for identifying CTE in vivo than neuroimaging modalities. 
Neuroimaging modalities are resource dependent, very expensive, and located in fixed buildings. 
Cerebral spinal fluid has been thought to be a prime biospecimen, but some challenges have been 
met, and not overcome. Although CSF is considered a potential source of TBI biomarkers given 
its direct contact with the brain and nervous system, the lumbar puncture required to sample CSF 
poses many disadvantages (Turner et al., 2013). Blood plasma has less risks than CSF lumbar 
punctures, but there are still some drawbacks including: dilution of the brain-specific protein by 
the large volume of plasma and in the extracellular fluid of peripheral organs, degradation of the 
biomarker candidate by blood proteases, clearance of the protein by hepatic metabolism or renal 
excretion, and analyses of brain proteins in blood that can be confounded by release of the same 
protein from peripheral tissues (DeKosky, Blennow, Ikonomovic, & Gandy 2013). 
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Currently, a definitive CTE diagnosis has only been confirmed with a post-mortem 
autopsy and immunohistochemistry for p-tau. It is believed that in the future, the use of 
biomarkers in along with diagnostic imaging such as PET and MRI will offer a promising 
opportunity for early diagnosis, monitoring of progression, and timely therapeutic interventions 
(Tharmartnam et al. 2018).  
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